Cumulative incidence (95% CI) of acute (grade 2-4) based on CMV serostatus and letermovir exposure
| Outcome . | CMV− . | CMV+/letermovir . | CMV+/no letermovir . | P value . |
|---|---|---|---|---|
| 1-y OS | 75% (68%, 83%) | 72% (64%, 81%) | 64% (50%, 81%) | .5 |
| 1-y EFS | 63% (55%, 72%) | 65% (57%, 75%) | 56% (43%, 74%) | .8 |
| 100-d grade 2-4 acute GVHD | 49% (40%, 57%) | 53% (43%, 62%) | 48% (31%, 62%) | .8 |
| Outcome . | CMV− . | CMV+/letermovir . | CMV+/no letermovir . | P value . |
|---|---|---|---|---|
| 1-y OS | 75% (68%, 83%) | 72% (64%, 81%) | 64% (50%, 81%) | .5 |
| 1-y EFS | 63% (55%, 72%) | 65% (57%, 75%) | 56% (43%, 74%) | .8 |
| 100-d grade 2-4 acute GVHD | 49% (40%, 57%) | 53% (43%, 62%) | 48% (31%, 62%) | .8 |
EFS, event-free survival.